Colorectal liver metastases: A changing treatment landscape

Journal of Oncology Practice

Volumn 12, Issue 1, 2016, Pages 40-41

  Brudvik, Kristoffer Watten ^a   Passot, Guillaume ^a   Vauthey, Jean Nicolas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL LIVER METASTASIS; COLORECTAL SURGERY; GENE MUTATION; HUMAN; LIVER RESECTION; METASTATIC COLORECTAL CANCER; MOLECULAR BIOLOGY; NOTE; ONCOLOGY; OPERATIVE BLOOD LOSS; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREOPERATIVE CARE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SYSTEMIC DISEASE; COLORECTAL TUMOR; LIVER TUMOR;

COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS;

EID: 84958524512     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2015.009746     Document Type: Note

References (10)

1. Dhir M, Sasson AR: Surgical management of liver metastases from colorectal cancer. J Oncol Pract 12:33-39, 2016
2. Wagner JS, Adson MA, Van Heerden JA, et al: The natural history of hepatic metastases from colorectal cancer: A comparison with resective treatment. Ann Surg 199:502-508, 1984
3. Saltz LB, Cox JV, Blanke C, et al: Irinotecan Study Group: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
4. Shindoh J, Loyer EM, Kopetz S, et al: Optimal morphologic response to preoperative chemotherapy: An alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30:4566-4572, 2012
5. Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230:309-318, discussion 318-321, 1999
6. Andreou A, Kopetz S, Maru DM, et al: Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg 256:642-650, 2012
7. Blazer DG III, Kishi Y, Maru DM, et al: Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26:5344-5351, 2008
8. Brudvik KW, Kopetz SE, Li L, et al: Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 102:1175-1183, 2015
9. Brouquet A, Abdalla EK, Kopetz S, et al: High survival rate after two-stage resection of advanced colorectal liver metastases: Response-based selection and complete resection define outcome. J Clin Oncol 29:1083-1090, 2011
10. Mise Y, Kopetz S, Mehran RJ, et al: Is complete liver resection without resection of synchronous lung metastases justified? Ann Surg Oncol 22:1585-1592, 2015